Nasdaq · Healthcare
NeuroPace Inc (NPCE)
As-reported financials and recent SEC filings for NeuroPace Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$100.0M
Net income
$-21.5M
Net margin
-21.5%
Diluted EPS
$-0.66
ROE
-112.8%
P/E (TTM)
—
Market cap
—
Debt / equity
3.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Operating income | $-16.3M | $-21.7M | $-27.2M | $-40.8M | $-23.7M |
| Net income | $-21.5M | $-27.1M | $-33.0M | $-47.1M | $-36.1M |
| Diluted EPS | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on NPCE
Search NeuroPace Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.